| Literature DB >> 33967796 |
Kang Geng1,2,3,4,5,6, Xiumei Ma1,2,3,4, Zongzhe Jiang3,4, Wei Huang7,3,4, Chenlin Gao7,3,4, Yueli Pu3,4, Lifang Luo3,4, Youhua Xu1,2, Yong Xu1,2,3,4,7.
Abstract
A growing body of evidence suggests that the interaction between immune and metabolic responses is essential for maintaining tissue and organ homeostasis. These interacting disorders contribute to the development of chronic diseases associated with immune-aging such as diabetes, obesity, atherosclerosis, and nonalcoholic fatty liver disease. In Diabetic wound (DW), innate immune cells respond to the Pathogen-associated molecular patterns (PAMAs) and/or Damage-associated molecular patterns (DAMPs), changes from resting to an active phenotype, and play an important role in the triggering and maintenance of inflammation. Furthermore, the abnormal activation of innate immune pathways secondary to immune-aging also plays a key role in DW healing. Here, we review studies of innate immune cellular molecular events that identify metabolic disorders in the local microenvironment of DW and provide a historical perspective. At the same time, we describe some of the recent progress, such as TLR receptor-mediated intracellular signaling pathways that lead to the activation of NF-κB and the production of various pro-inflammatory mediators, NLRP3 inflammatory via pyroptosis, induction of IL-1β and IL-18, cGAS-STING responds to mitochondrial injury and endoplasmic reticulum stress, links sensing of metabolic stress to activation of pro-inflammatory cascades. Besides, JAK-STAT is also involved in DW healing by mediating the action of various innate immune effectors. Finally, we discuss the great potential of targeting these innate immune pathways and reprogramming innate immune cell phenotypes in DW therapy.Entities:
Keywords: diabetic wound; inflammation; innate immunity; senescence; wound healing
Year: 2021 PMID: 33967796 PMCID: PMC8097165 DOI: 10.3389/fphar.2021.653940
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Markers of immune cells that can be used for diagnosis and/or treatment in DW.
| Immune cells | Differentiation markers | Diagnosis and/or treatment |
|---|---|---|
| T Cells | Effector T-cells↑ | The accumulation of effector T-cells is the core of DFU, diminish T-cells activation and tissue accumulation may accelerate DW healing |
| Memory T-cells↑ | ||
| Naive T-cells↓ | ||
| B Cells | BAFF↑ | The BAFF levels were superior to that of CRP levels in diagnosing DFU |
| Neutrophils (PMNs). | NETs↑ | PAD4 inhibition and cleavage of NETs by dnaseⅠmay improve DW healing |
| PAD4, H3Cit↑ | ||
| NET-specific markers | NET-specific markers H3Cit negatively correlated with wound healing in DFU patients | |
| H3Cit↑ | ||
| C5a↑ | Inhibitor of complement C1 ( PIC1). may reduce the infiltration of PMNS and improve DW healing | |
| C3-fragment deposition↑ | ||
| Monocytes/Macrophages (Mo/Mp). | Proportions of bone MyP↑circulating Ly6CHi Mo↑ | Myeloid lineage commitment in BM may contribute to increased mp numbers observed in DW strategies to regulate monopoiesis during homeostasis or post wounding may improve DW healing |
| Spleen Ly6CHi Mo↑ | ||
| HSPC response↑ | ||
| MPP2, MMP-3↓ | ||
| The influx of Ly6CHi Mo↑ | Time-dependent control of Mo/Mp influx after an injury such as anti-mcp-1 antibody may represent a novel therapeutic target for impaired DW healing | |
| Maturation to Ly6CLo Mo↓ | ||
| IL-1β, MMP-9, TNF-α↑ | Inhibiting IL-1β downregulate proinflammatory mp and upregulate prohealing mp in DW which may improve DW healing | |
| CD206, IGF-1↓ | ||
| TGF-β, il-10↓ | ||
| CD68, iNOS, TNF-α, IFN-γ↑ | Blocking the AGE-RAGE interaction may improve the function of Mp | |
| CD206, PDGF↓ | ||
| Jmjd3, IL-12↑ | Histone demethylase inhibitor such as GSK-J4 may improve chronic inflammation and DW healing | |
| H3K27me3↓ | ||
| UA, XO↑ | IFNβ may be an attractive therapeutic target and XO inhibitors such as allopurinol may reduce the production of IL-1β and improve DW healing | |
| Setdb2, H3K9me3↓ | ||
| IFNβ↓ | ||
| Mp senescence↑ | CXCR2 antagonist treatment such as SB265610 reduces inflammation Immune-aging and improve DW healing | |
| CXCR2↑ | ||
| SASP↑ |
Partial Abbreviations: BAFF: B-cell activating factor, PAD4: Peptidylarginine deiminase 4 (encoded by Padi4 in mice)., H3Cit: Citrullinated histone H3, NETs: Neutrophil extracellular traps, BM: Bone marrow, HSPC: Hematopoietic stem and progenitor cell, MyP: Marrow myeloid progenitors, MPP: Multipotent progenitor, Ly6CHi: CX3CR1lowCCR2+Ly6C+, Ly6CLo: CX3CR1highCCR2-Ly6C−, IL-1β: Interleukin-1β, TNF-α: Tumor necrosis factor-α, MMP-9: Matrix metalloprotein-9, IL-10: Interleukin-10, TGF-β: Transforming growth factor-β, IGF-1: Insulin-like growth factor-1, AGEs: Advanced glycation end products, PDGF: Platelet derived growth factor, Jmjd3: JumanjiC (JmjC) domain-containing protein, UA: Uric acid, XO: Xanthine oxidase, SASP: Senescence-associated secretory phenotype.
FIGURE 1Immune- Aging and Inflamm-Aging under Metabolic Stress in DW. ①Acute inflammation-mediated wound healing, tissue remodeling, and other orderly outcomes under the immune response in Non-DW. ②Inflamm-aging induced by metabolic pressure mediated tissue damage and hinders wound healing in DW. ③In the process cell senescence in DW, adaptive immunity significantly decreased, which is called immune-aging, while innate immunity is activated, thus inducing a unique pro-inflammatory response, which is called inflamm-aging.
Function and relationship of Mo/Mp subpopulations in wound homeostasis and repair.
| Mo/Mp | Function | ||
|---|---|---|---|
| Feature the steady-state | Wound healing | ||
| Ly6C+ ( | CCL2 can regulate its chemotactic activity | 1.A precursor of the TRMs | 1.Upregulate TNF-α, IL-1β |
| 2.Activate a function similar to M1 | |||
| 2.A precursor of Ly6C− in blood and bone marrow | 3.Die in the wound during the inflammatory, repair, proliferation period | ||
| 4.Enter the non-lymphoid organs and circulated to the lymph nodes | |||
| Ly6C− ( | Fractalkine (CX3CL1) can regulate its chemotactic activity | 1.Patrol the signs of endothelial inflammation or injury | 1.Upregulate TGF-β, VEGF |
| 2.Produce inflammatory mediators and coordinate the repair of damaged vascular endothelium | 2.Activate a function similar to M2 | ||
| TRMs F4/80+ ( | Bone marrow/Circulation | Local proliferation and self-renewal of mature differentiated cells without changing their differentiation phenotype | 1.Involve in the induction of inflammation |
| 2. Compensatory regulation through early recruitment and late self-proliferation | |||
| 3. Activate a function similar to M2 | |||
| WAMs F4/80− ( | M1 | GM-CSF, IFN-γ, TNF-α, LPS induce | 1.M1 has the function of promoting inflammation |
| M2 | M2a: IL-4, IL-13 induce | 2.M2 has the function of anti-inflammatory, repairing tissue, promoting angiogenesis | |
| M2b: Immune complexes, TLR receptor agonists, IL-1 receptor agonists induce | 3.M2a promote matrix reconstruction and tissue repair | ||
| M2c: IL-10, TGF-β, glucocorticoid induce | 4.M2b and M2c mainly play the function of immune regulation | ||
Partial Abbreviations: CCL2: Chemokine C-C-motif ligand 2, TRMs: Tissue-resident macrophages, TNF-α: Tumor necrosis factor-α, IL: Interleukin, CX3CL1: Chemokine C-X3-C-motif Ligand 1, TLR: Toll-like receptor, TGF-β: Transforming growth factor-β, VEGF: Vascular endothelial growth factor, WAMs: Wound-associated macrophages, GM-CSF: Granulocyte-macrophage colony-stimulating factor, LPS: Lipopolysaccharide.
FIGURE 2Proinflammatory microenvironment in DW due to dysregulation of immune and metabolic responses. Metabolic stress such as hyperglycemia, oxidative stress, AGEs, and hypoxia acted as the initiators of PAMPs and DAMPs to activate PRRs. Inducing infiltration of innate immune cells and activation of innate immune pathways, regulating the balance between innate immunity and inflammatory microenvironment, forming a pro-inflammatory microenvironment, and participating in DW healing. Partial abbreviation: IL-1β: Interleukin-1β, IL-6: Interleukin-6, TNF-α: Tumor necrosis factor-α, MMP-9: Matrix metalloprotein-9, NO: Nitric oxide, IL-10: Interleukin-10, IL-8: Interleukin-8, TGF-β: Transforming growth factor-β, DAMPs: Damage-associated molecular patterns, PAMPs: Pathogen-associated molecular patterns, TLR: Toll-like receptor.
FIGURE 3The regulatory relationship between different innate immune pathways in DW and homeostasis. The effects of the regulatory relationship between TLR, JAK-STAT, NLPR3, cGAS-STING signal pathways, and homeostasis in DW. After the formation of DW, PAMPs and DAMPs activate PRRs as initiating factors, inducing the activation of TLR, NLPR3, and cGAS-STING signal pathways, activate the expression of type I interferon and other immunoregulatory molecules. JAK-STAT mediates extracellular-nuclear regulation of various cytokines/chemokines. Mitochondrial damage, endoplasmic reticulum stress, and lysosomal membrane permeabilization are involved in the activation and regulation of signal pathways. Mitochondrial autophagy and apoptosis play an immune silencing role in maintaining immune homeostasis. A, B, C, and D represent four signaling pathways respectively.
Effects of modulating innate immunity pathways in experimental DW.
| Innate immune pathway | Knockout mice models | Intervention (agent) | Mechanism |
|---|---|---|---|
| TLR signaling | TLR2−/− | — | TLR2/6-MyD88-NF-κb↓ |
| IL- 1β, TNF-α↓ | |||
| DW Healing ↑ | |||
| TLR4−/− | — | TLR4-NF-κb↓ | |
| IL-6, TNF-α↓ | |||
| DW Healing ↑ | |||
| Leprdb/db | nAChR agonists (nicotine). | TLR2-NF-κb↓ | |
| AMP, IL-6↓ | |||
| DW Healing ↑ | |||
| TLR3−/− | REG3A | IL-33, REG3A/ RegIIIγ ↑ TLR3–JNK2 ↓ IL-6, TNF-α↓ | |
| JNK2−/− | SHP-1 inhibitor (SSG). | DW Healing ↑ | |
| Mll1f/fLyz2Cre+ | TLR4 inhibition | MLL1-mediated H3K4me3 ↑ TLR4-MyD88↓ | |
| TLR4−/− | (TAK-242). | DW Healing↑ | |
| NLRP3 inflammasome | Leprdb/db
| HS | NLRP3 inflammasome-caspase-1-il-1β/il-18 axis↓ |
| I-κb kinase-β inhibitor (BAY 11–7,082). | IL-1β, IL-18↓ | ||
| Purinergic P2X7 receptor inhibitor (brilliant blue G). | DW Healing ↑ | ||
| — | PPARα agonists (Fenofibrate). | ROS/TXNIP-NLRP3 inflammasome-caspase-1-il-1β/il-18 axis↓ | |
| DW Healing ↑ | |||
| — | NLRP3 inhibitor (MCC950). | TLR-4/TLR-9-NF-κb↓ | |
| TLR-4 inhibitor (CLI-095). | ROS/TXNIP-NLRP3 inflammasome-caspase-1-il-1β/il-18 axis↓ | ||
| TLR-9 inhibitor (ODN 2088). | IL-1β, IL-18↓ | ||
| ROS inhibitor (NAC, dnase I). | DW Healing ↑ | ||
| Leprdb/db | ROS inhibitor (NAC, dnase I). | NLRP3 inflammasome-caspase-1-il-1β/il-18 axis↓ IL-1β, IL-18↓ | |
| IL-1β blocking antibody (IL-1R1). | DW Healing ↑ | ||
| Glyburide caspase-1 inhibitor (YVAD). | |||
| cGAS-STING signaling | STING−/- | — | Mitochondrial damage-cGAS-STING-IRF3 ↓ ICAM-1↓ |
| Improve IR, Glucose intolerance | |||
| JAK-STAT signaling | Leprdb/db | — | IL-12-Stat4↑ |
| CCL2-CCR2↑ | |||
| DW Healing ↓ | |||
| — | — | IL-6 -il-6rα-jak-stat3↑ | |
| SCOS3, DW Healing ↓ |
Partial abbreviation: TLR: Toll-like receptor, STZ: Streptozotocin, NF-κB: Nuclear factor-κB, IL: Interleukin, TNF-α: Tumor necrosis factor-α, nAChRs: Nicotinic acetylcholine receptors, AMP: Adenosine monophosphate, REG3A: Regenerating islet-derived protein 3A, SHP-1: domain-containing protein-tyrosine phosphatase-1, HS: Heparan sulfate, PPARα: Peroxisome proliferator-activated receptors α, EPC: Endothelial progenitor cells, IGF-1: Insulin-like growth factor-1, TGF-β: Transforming growth factor-β, IR: Insulin resistance.